Twinbeech Capital LP Takes $3.05 Million Position in HCA Healthcare, Inc. (NYSE:HCA)

Twinbeech Capital LP acquired a new stake in HCA Healthcare, Inc. (NYSE:HCA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,169 shares of the company's stock, valued at approximately $3,052,000.

Several other hedge funds also recently modified their holdings of HCA. Congress Wealth Management LLC DE lifted its position in HCA Healthcare by 3.4% in the fourth quarter. Congress Wealth Management LLC DE now owns 1,039 shares of the company's stock worth $312,000 after purchasing an additional 34 shares during the period. Evergreen Private Wealth LLC lifted its position in HCA Healthcare by 0.3% in the fourth quarter. Evergreen Private Wealth LLC now owns 12,787 shares of the company's stock worth $3,838,000 after purchasing an additional 35 shares during the period. Mediolanum International Funds Ltd lifted its position in HCA Healthcare by 0.3% in the fourth quarter. Mediolanum International Funds Ltd now owns 10,592 shares of the company's stock worth $3,153,000 after purchasing an additional 36 shares during the period. Prairie Wealth Advisors Inc. lifted its position in HCA Healthcare by 6.1% in the fourth quarter. Prairie Wealth Advisors Inc. now owns 700 shares of the company's stock worth $210,000 after purchasing an additional 40 shares during the period. Finally, Whittier Trust Co. lifted its position in HCA Healthcare by 3.6% in the fourth quarter. Whittier Trust Co. now owns 1,195 shares of the company's stock worth $359,000 after purchasing an additional 41 shares during the period. 62.73% of the stock is owned by institutional investors.

HCA Healthcare Price Performance

HCA Healthcare stock opened at $385.95 on Wednesday. The business's 50-day simple moving average is $343.61 and its 200 day simple moving average is $328.91. The stock has a market cap of $92.85 billion, a price-to-earnings ratio of 17.57, a P/E/G ratio of 1.10 and a beta of 1.46. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $417.14. The company has a quick ratio of 0.97, a current ratio of 1.08 and a debt-to-equity ratio of 69.07.

HCA Healthcare (NYSE:HCA - Get Free Report) last issued its earnings results on Friday, April 25th. The company reported $6.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.75 by $0.70. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. The firm had revenue of $18.32 billion for the quarter, compared to analysts' expectations of $18.26 billion. During the same quarter last year, the business earned $5.36 earnings per share. The company's revenue was up 5.7% compared to the same quarter last year. As a group, research analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 16th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date is Monday, June 16th. HCA Healthcare's dividend payout ratio (DPR) is currently 12.81%.

Insiders Place Their Bets

In other HCA Healthcare news, COO Jon M. Foster sold 15,698 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $369.32, for a total transaction of $5,797,585.36. Following the transaction, the chief operating officer now owns 12,646 shares of the company's stock, valued at $4,670,420.72. The trade was a 55.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

HCA has been the subject of several recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $405.00 price objective on shares of HCA Healthcare in a research note on Monday, January 27th. Guggenheim initiated coverage on HCA Healthcare in a research note on Wednesday, April 9th. They set a "neutral" rating for the company. StockNews.com upgraded HCA Healthcare from a "hold" rating to a "buy" rating in a research note on Monday, April 28th. Bank of America dropped their price objective on HCA Healthcare from $380.00 to $370.00 and set a "buy" rating for the company in a research note on Monday, January 27th. Finally, Barclays dropped their price objective on HCA Healthcare from $392.00 to $366.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, HCA Healthcare currently has an average rating of "Moderate Buy" and a consensus price target of $381.13.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.